Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 400 Shares of Stock

Key Points

• ANI Pharmaceuticals VP Meredith Cook sold 400 shares of the company's stock at an average price of $98.42, totaling $39,368, which decreased her ownership by 0.52%.
• The company's stock recently traded up by 1.1%, reaching $98.81, with a twelve-month high of $99.50 and a market capitalization of $2.14 billion.
• ANI Pharmaceuticals reported $1.80 earnings per share, exceeding analyst expectations, with a quarterly revenue increase of 53.2% year-over-year.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $98.42, for a total transaction of $39,368.00. Following the completion of the sale, the vice president owned 76,074 shares in the company, valued at $7,487,203.08. This represents a 0.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Wednesday, August 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $88.87, for a total transaction of $35,548.00.
• On Monday, July 14th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $64.88, for a total transaction of $25,952.00.

ANI Pharmaceuticals Stock Up 1.1%

Shares of ANIP traded up $1.10 on Monday, reaching $98.81. The company's stock had a trading volume of 340,782 shares, compared to its average volume of 423,880. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $99.50. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The firm has a fifty day moving average of $80.19 and a 200-day moving average of $70.09. The stock has a market capitalization of $2.14 billion, a PE ratio of 19.01 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same period in the prior year, the firm posted $1.02 EPS. The firm's quarterly revenue was up 53.2% compared to the same quarter last year. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ANIP. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after purchasing an additional 510 shares during the period. Newbridge Financial Services Group Inc. raised its position in shares of ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock worth $39,000 after buying an additional 400 shares in the last quarter. State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth $50,000. Finally, National Bank of Canada FI purchased a new stake in shares of ANI Pharmaceuticals in the first quarter worth $79,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. HC Wainwright reissued a "buy" rating and set a $93.00 target price (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Piper Sandler reissued an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $88.25.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.